BioFIT 2017 conference programme is designed to address the needs of its audience constituted by academia, TTOs, research institutions, pharma, biotech companies, but also law experts and investors in seed and Series A. BioFIT conference programme aims at providing solutions, best practices for each player of the sector.

BioFIT 2017 cutting-edge programme is remodelled around three tracks:

  • Track 1: New players involved in innovation in the health sector
  • Track 2: Maturing and licensing early-stage assets
  • Track 3: Bioentrepreneurs’ challenges at the seed and Series A stages

BioFIT 2017 conference programme’s goal is to put bioentrepreneurship at its heart, explore the heated and beneficial relationships between academia and industry, address access to seed capital and overseeing new trends in financing early-stage innovation.

BioFIT 2017 conference programme reflects the fast-paced, dynamic and evolving sector of Life Sciences.


PLENARY SESSION:
HOW TO OVERCOME THE SHORTAGE OF BIOENTREPRENEURS IN EUROPE?


Europe is benefitting from a unique density of academic research and has now also a lot improved the access to equity investment. What Europe lacks today is bioentrepreneurs. How to attract entrepreneurs towards Life sciences? How to turn talented scientists into entrepreneurs? Can the support from technology transfer, incubators and early investors provide sufficient mentorship and a strong network?


TRACK 1:
NEW PLAYERS INVOLVED IN INNOVATION IN THE HEALTH SECTOR

Big data and health IT companies bring a key expertise to potentially increase efficiency in the discovery, the preclinical and clinical stages of development. What will be their precise status and commitment in the chain of therapeutic innovations: Contributing or partly leading? Examples of collaborations between biotech, pharma and academic research will be highlighted. However those new players are not only coming from the big data sectors, they will also come from various areas such as animal health or e-health.


TRACK 2:
MATURING & LICENSING EARLY-STAGE ASSETS


Early-stage assets evolve in an ecosystem in which TTOs, scientists and entrepreneurs are tightly interconnected. Assessing opportunities in licensing early-stage projects, discussing the TTO’s mentoring role and exploring the scientists’ commitment. This track aims at underlining the long and hard road that maturing early-stage assets is. How to more frequently and more efficiently turn science into business?


TRACK 3:
BIOENTREPRENERS’ CHALLENGES AT THE SEED & SERIES A STAGES


Having the right mindset, a solid presentation and a fundable project are not the sole problems that bioentrepreneurs’ must face at the seed and Series A stages. What are the seed and Series A investors awaiting in terms of maturity of projects in 2017? How often are new types of early-stage investors involved in financing rounds (philantropic ventures, indications/technologies specialised ventures…)? How is the angels/seed investors relationship working? Are there more interactions and partnerships between pharma and VCs at those initial stages?


Back on BioFIT 2016 programme:

Focusing on current issues in Life Sciences, BioFIT 2016’s conference programme was composed of a varied and rich agenda, featuring the latest opinions on trending topics.
Supported by its prestigious Steering Committee, the sessions focused on three themes:
• Showcasing best practices in collaborative research
• Highlighting key issues in licensing and tech transfer
• Discussing early-stage innovation funding

2016 PLENARY SESSION


2016 TRACK 1:
BEST PRACTICES IN COLLABORATIVE RESEARCH

The recent rising popularity of the open innovation model has led pharmas, biotechs and academia to consider this as a win-win opportunity. Many types of partnerships have been developed and tested to analyze their strengths and weaknesses and how they advance innovation. We will debate the potential of this exciting, emerging model in cross sector collaborations as a new driver for rapid market access.

” Recent developments such as mobile health devices and big data are transforming the way we translate medical advances into new medicines. This track highlights how academia and industry are taking a more open and networked collaboration approach to improve the quality and richness of biomedical research. ”

Adrian CARTER
Corporate Vice-President, Global Research Networking, Boehringer Ingelheim (Germany)


2016 TRACK 2:
KEY ISSUES IN LICENSING AND TECH TRANSFER

While academia aims to highlight knowledge and innovation, industry’s goal is to leverage this expertise and bring it to market. However, when an innovation appears from academia as a spin off or as a transferred license, many IP, due diligence, management and financing challenges arise. This track will discuss the processes and models available and the consequences on translational research.

“Pharma and biotech are looking increasingly towards academia for open innovation, explorative research and early stage discovery. But is academia prepared? Are the appropriate models and mechanisms in place to professionalise licensing and facilitate technology transfer? What about spin-outs and start-ups? Are the initial terms reasonable or a kiss of death? This track will challenge the current status of academic – industry relations. “

Ivan BAINES
Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (Germany)


2016 TRACK 3:
EARLY STAGE INNOVATION: IDENTIFY THE RIGHT SOURCES of FUNDING

In a difficult economic climate, in which investors prefer to fund later stage companies, finding financial resources to progress your early stage project is challenging. In this track, we will discuss how VCs assess risk, non-traditional funding mechanisms available to finance early stage innovation and what a young biotech should do in order to attract investors.

“It is critical to find funding for early stage innovation and it is challenging to know what sources are available. Funding in the future will most certainly evolve. What will the trends be? It is therefore important to hear about inspirational ideas regarding different solutions in the US and Europe.”

Gunilla EKSTRÖM
Vice President Operations, Karolinska Development (Sweden)